Tatsuya Morimoto

Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Japan

Articles by Tatsuya Morimoto

Randomised Double-blind Placebo-Controlled Multicentre Trial for the Effects of Yokukansan in Smokers with Depressive Tendencies

Maki Komiyama, Yuka Ozaki, Hiromichi Wada, et al

Published:

Citation: European Cardiology Review 2023;18:e30.

The Natural Product Zerumbone Suppresses Pressure Overload-Induced Cardiac Dysfunction by Inhibiting Cardiac Hypertrophy and Fibrosis

Mikuto Tojima, Yasufumi Katanasaka, Yoichi Sunagawa, et al

Published:

Citation: European Cardiology Review 2021;16:e70.

A Novel Curcumin Formulation, ASD-Cur, Suppressed the Development of Systolic Dysfunction After Myocardial Infarction in Rats

Hidemichi Takai, Yoichi Sunagawa, Masafumi Funamoto, et al

Published:

Citation: European Cardiology Review 2021;16:e69.

The Polyunsaturated Fatty Acids EPA and DHA Prevent Myocardial Infarction-induced Heart Failure by Inhibiting p300-HAT Activity in Rats

Yoichi Sunagawa, Ayumi Katayama, Masafumi Funamoto, et al

Published:

Citation: European Cardiology Review 2021;16:e68.

Discovery of Novel Small Molecules for Heart Failure Therapy Using Cultured Cardiomyocyte by High Throughput Screening Assay

Satoshi Shimizu, Miho Yamada, Takahiro Katagiri, et al

Published:

Citation: European Cardiology Review 2021;16:e66.

Chrysanthemum morifolium Extract Prevents the Development of Doxorubicin-induced Heart Failure

Masaya Ono, Yoichi Sunagawa, Yasufumi Katanasaka, et al

Published:

Citation: European Cardiology Review 2021;16:e65.

Anti-inflammatory Action of Curcumin and Its Use in the Treatment of Lifestyle-related Diseases

Kana Shimizu, Masafumi Funamoto, Yoichi Sunagawa, et al

Published:

Citation: European Cardiology Review 2019;14(2):117–22

Erratum to: The Inhibitory Effects of Crucumin Glucuronide on p300-HAT Activity and Hypertrophic Phenylephrine- Induced Responses in Cardiomyocytes

Mai Genpei, Yoichi Sunagawa, Masafumi Funamoto, et al

Citation: European Cardiology Review 2018;13(2):136.

Analysis of the Effects of EPA and DHA on Cardiomyocyte hypertrophy

Ayumi Katayama, Masafumi Funamoto, Kana Shimizu, et al

Citation: European Cardiology Review 2018;13(2):121.

The GATA4 Acetylation Site Plays a Key Role in the Development of Cardiomyocyte Hypertrophy

Satoshi Shimizu, Yoichi Sunagawa, Kodai Hara, et al

Citation: European Cardiology Review 2018;13(2):125.

TBL1 Suppresses Cardiomyocyte Hypertrophy by Regulating the Interaction Between HDAC3 and GATA4

Yasufumi Katanasaka, Masatoshi Namiki, Yoichi Sunagawa, et al

Citation: European Cardiology Review 2018;13(2):126.

A PRMT5 Selective Inhibitor EPZ015666 Suppressed TAC-induced Left Ventricular Dysfunction

Kazuma Hanajima, Yusuke Miyazaki, Yasufumi Katanasaka, et al

Citation: European Cardiology Review 2018;13(2):130.

Nobiletin a Citrus Flavonoid, Exerts Additional Effects with Angiotensin II Receptor Blocker on Systolic Function in Salt-sensitive Dahl Rats

Haruka Ebi, Masafumi Funamoto, Yoichi Sunagawa, et al

Citation: European Cardiology Review 2017;12(2):92.

Effects of Pharmacotherapy for Smoking Cessation on LOX Index, a Cardiovascular Risk Marker

Maki Komiyama, Hiromichi Wada, Hajime Yamakage, et al

Citation: European Cardiology Review 2017;12(2):96.

A Transcriptional Co-activator, p300 is Involved in the Epigenetic Gene Activation on Hypertrophic Response Gene Promoters in Heart Failure

Masafumi Funamoto, Yoichi Sunagawa, Yasufumi Katanasaka, et al

Citation: European Cardiology Review 2017;12(2):110.